Still's disease (Systemic-Onset Juvenile Idiopathic Arthritis);Maladie de Still (forme systémique d'arthrite juvénile idiopathique)

Archives de Pediatrie

Volumn 15, Issue 5, 2008, Pages 865-866

  Quartier, P ^a  

^a ASSISTANCE PUBLIQUE HÔPITAUX DE PARIS   (France)

Author keywords

[No Author keywords available]

Indexed keywords

ATLIZUMAB; CORTICOSTEROID; INDOMETACIN; INTERLEUKIN 6; METHOTREXATE; RECOMBINANT INTERLEUKIN 1 RECEPTOR BLOCKING AGENT;

ARTICLE; ELECTROMYOGRAM; HUMAN; JUVENILE RHEUMATOID ARTHRITIS; PATHOPHYSIOLOGY;

ARTHRITIS, JUVENILE RHEUMATOID; CHILD; HUMANS; METHOTREXATE; RANDOMIZED CONTROLLED TRIALS AS TOPIC; RECEPTORS, INTERLEUKIN-1;

EID: 45449120632     PISSN: 0929693X     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0929-693X(08)71944-4     Document Type: Article

References (11)

1. Petty R.E., Southwood T.R., Baum J., et al. Revision of the proposed classification criteria for juvenile idiopathic arthritis: Durban, 1997. J Rheumatol 25 (1998) 1991-1994
2. Hofer M.F., Mouy R., and Prieur A.M. Juvenile idiopathic arthritides evaluated prospectively in a single center according to the Durban criteria. J Rheumatol 28 (2001) 1083-1090
3. Woo P., Southwood T.R., Prieur A.M., et al. Randomized, placebo-controlled, crossover trial of low-dose oral methotrexate in children with extended oligoarticular or systemic arthritis. Arthritis Rheum 43 (2000) 1849-1857
4. Quartier P., Taupin P., Bourdeaut F., et al. Efficacy of etanercept for the treatment of juvenile idiopathic arthritis according to the onset type. Arthritis Rheum 48 (2003) 1093-1101
5. Giannini E.H., Lovell D.J., Silverman E.D., et al. Intravenous immunoglobulin in the treatment of polyarticular juvenile rheumatoid arthritis:a phase I/II study. Pediatric Rheumatology Collaborative Study Group. J Rheumatol 23 (1996) 919-924
6. Singh-Grewal D., Schneider R., Bayer N., et al. Predictors of disease course and remission in systemic juvenile idiopathic arthritis: significance of early clinical and laboratory features. Arthritis Rheum 54 (2006) 1595-1601
7. Lehman T.J., Schechter S.J., Sundel R.P., et al. Thalidomide for severe systemic onset juvenile rheumatoid arthritis:A multicenter study. J Pediatr 145 (2004) 856-857
8. Yokota S., Miyamae T., Imagawa T., et al. M. Clinical study of tocilizumab in children with systemic-onset juvenile idiopathic arthritis. Clin Rev Allergy Immunol 28 (2005) 231-238
9. Pascual V., Allantaz F., Arce E., et al. Role of interleukin-1 (IL-1) in the pathogenesis of systemic onset juvenile idiopathic arthritis and clinical response to IL-1 blockade. J Exp Med 201 (2005) 1479-1486
10. Lequerré T., Quartier P., Rosellini D., et al. Interleukin-1 receptor antagonist (anakinra) treatment in patients with systemic-onset juvenile idiopathic arthritis or adult onset Still's disease. Preliminary experience in France. Ann Rheum Dis 67 (2008) 302-308
11. Quartier P., Cimaz R., Pillet P., et al. Anakinra in Systemic-onset Juvenile Idiopathic Arthritis (ANAJIS trial):preliminary results (2007), Congès de l'American College of Rheumatology, Boston abstract CRCO2